[ Price : $8.95]
FDA grants Plus Therapeutics an orphan drug designation for Rhenium (186Re) Obisbemeda, a radiotherapy for treating leptomeningeal...[ Price : $8.95]
Federal Register notice: FDA makes available its decision to deny a request for a hearing on a CDER recent refusal to approve a Va...[ Price : $8.95]
Johnson & Johnson stops its Phase 3 VENTURA development program evaluating aticaprant as an adjunctive treatment for major depress...[ Price : $8.95]
Consultants from Eliquent Life Sciences say most of FDAs drug inspection-based Warning Letters issued in fiscal year 2024 went to ...[ Price : $8.95]
FDA approves a Celltrion BLA for Omlyclo, the first interchangeable biosimilar to Genentechs Xolair (omalizumab).[ Price : $8.95]
FDA denies a hearing on Vandas Hetlioz sNDA and proceeds with its rejection of the filing.[ Price : $8.95]
FDA says a Nuwellis 12/2024 recall of certain lots of its extracorporeal blood circuits is Class 1.[ Price : $8.95]
FDA approves a Neurotech Pharmaceuticals BLA for Encelto (revakinagene taroretcel-lwey) for treating macular telangiectasia Type 2...